HK1223795A1 - 拉喹莫德響應性的基因表達生物標誌物 - Google Patents

拉喹莫德響應性的基因表達生物標誌物

Info

Publication number
HK1223795A1
HK1223795A1 HK16112324.4A HK16112324A HK1223795A1 HK 1223795 A1 HK1223795 A1 HK 1223795A1 HK 16112324 A HK16112324 A HK 16112324A HK 1223795 A1 HK1223795 A1 HK 1223795A1
Authority
HK
Hong Kong
Prior art keywords
laquinimod
responsiveness
gene expression
expression biomarkers
biomarkers
Prior art date
Application number
HK16112324.4A
Other languages
English (en)
Inventor
Hayardeny Liat
Achiron Anat
Gurevich Michael
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of HK1223795A1 publication Critical patent/HK1223795A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/285Demyelinating diseases; Multipel sclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
HK16112324.4A 2013-09-12 2016-10-26 拉喹莫德響應性的基因表達生物標誌物 HK1223795A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361877210P 2013-09-12 2013-09-12
US201461972782P 2014-03-31 2014-03-31
PCT/US2014/055502 WO2015038963A1 (en) 2013-09-12 2014-09-12 Gene expression biomarkers of laquinimod responsiveness

Publications (1)

Publication Number Publication Date
HK1223795A1 true HK1223795A1 (zh) 2017-08-11

Family

ID=52666348

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16112324.4A HK1223795A1 (zh) 2013-09-12 2016-10-26 拉喹莫德響應性的基因表達生物標誌物

Country Status (8)

Country Link
US (1) US20160201132A1 (zh)
EP (1) EP3043647A4 (zh)
JP (1) JP2016530892A (zh)
CA (1) CA2922958A1 (zh)
HK (1) HK1223795A1 (zh)
IL (1) IL244402A0 (zh)
MX (1) MX2016002987A (zh)
WO (1) WO2015038963A1 (zh)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
JP5986745B2 (ja) 2008-07-15 2016-09-06 アカデミア シニカAcademia Sinica Ptfe様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
AU2013306098A1 (en) 2012-08-18 2015-02-12 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
CN105682666B (zh) 2013-09-06 2021-06-01 中央研究院 使用醣脂激活人类iNKT细胞
TW201620939A (zh) 2014-01-16 2016-06-16 中央研究院 治療及檢測癌症之組合物及方法
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
TWI797430B (zh) 2014-03-27 2023-04-01 中央研究院 反應性標記化合物及其用途
AU2015267045B2 (en) 2014-05-27 2021-02-25 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR20170003720A (ko) 2014-05-27 2017-01-09 아카데미아 시니카 항-cd20 글리코항체 및 이의 용도
CA2950423A1 (en) 2014-05-27 2015-12-03 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
EP3154582A4 (en) 2014-05-28 2018-01-10 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
WO2016040369A2 (en) 2014-09-08 2016-03-17 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
EP3789766A1 (en) 2015-01-24 2021-03-10 Academia Sinica Novel glycan conjugates and methods of use thereof
WO2017100796A1 (en) * 2015-12-11 2017-06-15 SINACA, Academia Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
JP2019515876A (ja) 2016-03-08 2019-06-13 アカデミア シニカAcademia Sinica N−グリカンおよびそのアレイのモジュール合成のための方法
EP3481963A1 (en) * 2016-07-08 2019-05-15 Genentech, Inc. Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene.
CN109963868B (zh) 2016-08-22 2023-11-14 醣基生医股份有限公司 抗体、结合片段及使用方法
US20190336585A1 (en) * 2018-05-03 2019-11-07 John Lawrence Mee Method for sustainable human cognitive enhancement
US20190359985A1 (en) * 2018-05-22 2019-11-28 John Lawrence Mee Adjustable method for sustainable human cognitive enhancement
US20190390193A1 (en) * 2018-06-23 2019-12-26 John Lawrence Mee Reversible method for sustainable human cognitive enhancement
EP3586866A1 (en) * 2018-06-28 2020-01-01 Universität Zürich Immunodominant proteins and fragments in multiple sclerosis
WO2020163794A1 (en) * 2019-02-08 2020-08-13 Msdx, Inc. Detection of brain-derived debris in recirculating phagocytes
US11271935B2 (en) 2020-07-30 2022-03-08 Bank Of America Corporation Blind authenticator

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2392352B1 (en) * 2009-01-28 2017-10-25 Korea Research Institute of Bioscience and Biotechnology Cd93 or use of soluble fragment thereof
EP2414542B1 (en) * 2009-03-30 2017-08-30 Tel HaShomer Medical Research Infrastructure and Services Ltd. Methods of predicting clinical course and treating multiple sclerosis
US20130029916A1 (en) * 2011-07-28 2013-01-31 Yossi Gilgun Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate

Also Published As

Publication number Publication date
EP3043647A4 (en) 2017-05-10
MX2016002987A (es) 2016-10-07
EP3043647A1 (en) 2016-07-20
US20160201132A1 (en) 2016-07-14
WO2015038963A1 (en) 2015-03-19
JP2016530892A (ja) 2016-10-06
IL244402A0 (en) 2016-04-21
CA2922958A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
HK1223795A1 (zh) 拉喹莫德響應性的基因表達生物標誌物
HK1222466A1 (zh) 遺傳變異分析
IL244791A0 (en) Methods for modifying a host cell
SI3068881T1 (sl) Z nukleazo posredovano uravnavanje izražanja genov
LT3080100T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
SG11201510747RA (en) Method for increasing expression of rna-encoded proteins
HK1218014A1 (zh) 用以間接判定參考間距的方法
GB201316880D0 (en) Controlling disclosure of structured data
HK1222339A1 (zh) 金屬-β-內酰胺酶的抑制劑
IL240763B (en) The halopyrazoles as thrombin inhibitors
SG11201601919SA (en) Method of friction control
GB201313440D0 (en) Characterization of rice
HK1221159A1 (zh) 轉移抑制劑
GB201709321D0 (en) Improved method of data dependent control
GB2521478B (en) Control of data provision
GB201312311D0 (en) Uses of enzyme inhibitors
IL230063A0 (en) A technique to control selection order
GB201308639D0 (en) Biomarkers and uses of thereof
AU5220P (en) Jewel of DesertTopaz Delosperma cooperi
GB201322036D0 (en) New therapeutic uses of enzyme inhibitors
GB201313826D0 (en) Predicting of physical training response
GB201310488D0 (en) New therapeutic uses of enzyme inhibitors
GB201303264D0 (en) Method of control